thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-06 and is reviewed periodically as new material appears.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
=== Legal status === In December 2016, a new drug application was filed with the US Food and Drug Administration (FDA), and in October 2017, an FDA advisory committee approved it unanimously. In December 2017, the injectable version with the brand name Ozempic was approved in the US for use by people with diabetes, and, in January 2018, in Canada. In February 2018, authorization was granted in the European Union, in March 2018 in Japan, and in August 2019 in Australia. A version of semaglutide to treat diabetes that can be taken orally (Rybelsus) was approved for medical use in the US in September 2019, and in the European Union in April 2020. In January 2023, the US FDA prescription label for Rybelsus was updated to reflect that it can be used as a first-line treatment for adults with type 2 diabetes. In June 2021, a higher-dose version for injectable use, sold under the brand name Wegovy, was approved by the FDA as an anti-obesity medication for long-term weight management in adults. In January 2022, Wegovy was approved for medical use in the European Union. In December 2025, an oral version of semaglutide, sold under the brand name Wegovy, was approved in the US for weight management. In March 2026, the CHMP recommended granting a conditional marketing authorization for Kayshild (semaglutide), a GLP-1 receptor agonist for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, a serious disease where fat deposits accumulate in the liver causing inflammation.
== Career == Principal Scientist SCIEX - 1980-2005 Associate Professor (CLTA) at the University of Toronto, first in the Institute of Biomaterials and Biomedical Engineering (2005–2008) and then in Chemistry 2008–2013. President DVS Sciences 2004 - 2015 (acquired by Fluidigm in 2014) Adjunct Professor at York University in the Department of Chemistry 2015–2018
Flurpiridaz (18F), sold under the brand name Flyrcado, is a cyclotron-produced radioactive diagnostic agent for use with positron emission tomography (PET) myocardial perfusion imaging under rest or stress (pharmacologic or exercise). Flurpiridaz (18F) It is given by intravenous injection. The most common adverse reactions include dyspnea (shortness of breath), headache, angina pectoris (severe pain in the chest), chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia (irregular heartbeat). Flurpiridaz (18F) was approved for medical use in the United States in September 2024.
Sources: en.wikipedia.org
== Description == One of the beautiful, intelligent and smart fish,"The King betta" generally grows to about 5–6 cm (2–2 1/2 in). Its pigments are generally vibrant beige to a white. As with most bettas, King betta females are smaller (even the fins) and less colorful than the males. The king betta can be happy or even aggressive based on the environment and can be trained easily (rather than the wild bettas') and they remember their owners for longer time period. The life span of the King betta is short, generally 2–3 years, rarely reaching four. The King betta is (as are all other bettas) members of the gourami family (Osphronemidae) and prefers a temperature of 78–82 °F.
Many structures of water-soluble domains of ABC proteins have been produced in recent years. ATP-binding domain of ABC transporters Bacterial binding protein-dependent transporter Transmembrane domain of ABC transporters Elizabeth P. Carpenter, British structural biologist, first to describe structure of human ABC-transporter ABC10 Classification of ABC transporters in TCDB ABCdb Archaeal and Bacterial ABC Systems database, ABCdb ATP-Binding+cassette+transporters at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
==== Americas ==== Between 1963 and 1966, numerous scientific studies demonstrated the use of 99mTc as radiotracer or diagnostic tool. As a consequence the demand for 99mTc grew exponentially and by 1966, Brookhaven National Laboratory was unable to cope with the demand. Production and distribution of 99mTc generators were transferred to private companies. "TechneKow-CS generator", the first commercial 99mTc generator, was produced by Nuclear Consultants, Inc. (St. Louis, Missouri) and Union Carbide Nuclear Corporation (Tuxedo, New York). From 1967 to 1984, 99Mo was produced for Mallinckrodt Nuclear Company at the Missouri University Research Reactor (MURR). Union Carbide actively developed a process to produce and separate useful isotopes like 99Mo from mixed fission products that resulted from the irradiation of highly enriched uranium (HEU) targets in nuclear reactors developed from 1968 to 1972 at the Cintichem facility (formerly the Union Carbide Research Center built in the Sterling forest in Tuxedo, New York (41°14′6.88″N 74°12′50.78″W)). The Cintichem process originally used 93% highly enriched U-235 deposited as UO2 on the inside of a cylindrical target. At the end of the 1970s, 200,000 Ci (7.4×1015 Bq) of total fission product radiation were extracted weekly from 20 to 30 reactor bombarded HEU capsules, using the so-called "Cintichem [chemical isolation] process." The research facility with its 1961 5-MW pool-type research reactor was later sold to Hoffman-LaRoche and became Cintichem Inc. In 1980, Cintichem, Inc.
=== Duration === Most cases of discontinuation syndrome may last between one and four weeks and resolve on their own. Occasionally symptoms can last up to one year. They typically resolve within a day of restoring the medication. Paroxetine and venlafaxine seem to be particularly difficult to discontinue, and prolonged withdrawal syndrome (post-acute-withdrawal syndrome, or PAWS) lasting over 18 months has been reported with paroxetine.
Sources: en.wikipedia.org
=== Synthesis === Adrenochrome is readily synthesized from commercially available reagents: chloroacetic acid and catechol react in the presence of phosphoryl chloride to yield chloroacetylcatechol. After purification, chloroacetylcatechol is reacted with aqueous methylamine and treated with hydrochloric acid, yielding adrenalone hydrochloride. This is then hydrogenated to racemic adrenaline. Finally, adrenaline is oxidized to adrenochrome by an appropriate oxidizing agent such as silver oxide.
N-Methylformamide (NMF) is a colorless, nearly odorless, organic compound and secondary amide with molecular formula CH3NHCHO, which is a liquid at room temperature. NMF is mainly used as a reagent in various organic syntheses with limited applications as a highly polar solvent. NMF is closely related to other formamides, notably formamide and dimethylformamide (DMF). However, industrial use and production of NMF are far less than for either of these other formamides. DMF is favored over NMF as a solvent due to its greater stability. Annual production of NMF can be assumed to be significantly less than the production of either formamide (100,000 tons) or DMF (500,000 tons).
=== Dihydrolipoyl transacetylase (E2) === At this point, the lipoate-thioester functionality is translocated into the Dihydrolipoyl transacetylase (E2) active site, where a transacylation reaction transfers the acetyl from the "swinging arm" of lipoyl to the thiol of coenzyme A. This produces acetyl-CoA, which is released from the enzyme complex and subsequently enters the citric acid cycle. E2 can also be known as lipoamide reductase-transacetylase.
== Structure and processing == Human protein C is a vitamin K-dependent glycoprotein structurally similar to other vitamin K-dependent proteins affecting blood clotting, such as prothrombin, Factor VII, Factor IX and Factor X. Protein C synthesis occurs in the liver and begins with a single-chain precursor molecule: a 32 amino acid N-terminus signal peptide preceding a propeptide. Protein C is formed when a dipeptide of Lys198 and Arg199 is removed; this causes the transformation into a heterodimer with N-linked carbohydrates on each chain. The protein has one light chain (21 kDa) and one heavy chain (41 kDa) connected by a disulfide bond between Cys183 and Cys319.
By increasing farmers' incomes, this could reduce poverty. It would also open up area which farmers could use to diversify crops for household use. The World Bank claims to be part of the solution to malnutrition, asserting that countries can best break the cycle of poverty and malnutrition by building export-led economies, which give them the financial means to buy foodstuffs on the world market. Child malnutrition can worsen with food price inflation. The 2021 to 2023 food price surge is associated with higher rates of wasting among children under five years of age. A 10% increase in food prices is associated with a 2.7% to 4.3% rise in overall wasting and a 4.8 to 6.1 percent increase in severe wasting among children under five years of age.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.